Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Non-Current Liabilities (2019 - 2021)

IDEAYA Biosciences' Total Non-Current Liabilities history spans 3 years, with the latest figure at $81.8 million for Q3 2021.

  • For Q3 2021, Total Non-Current Liabilities fell 22.78% year-over-year to $81.8 million; the TTM value through Sep 2021 reached $81.8 million, down 22.78%, while the annual FY2020 figure was $100.0 million, 695.6% up from the prior year.
  • Total Non-Current Liabilities for Q3 2021 was $81.8 million at IDEAYA Biosciences, down from $88.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $105.9 million in Q3 2020 and bottomed at $11.9 million in Q3 2019.
  • The 3-year median for Total Non-Current Liabilities is $47.2 million (2019), against an average of $53.1 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 792.3% in 2020 before it fell 22.78% in 2021.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $12.6 million in 2019, then skyrocketed by 695.6% to $100.0 million in 2020, then decreased by 18.18% to $81.8 million in 2021.
  • Per Business Quant, the three most recent readings for IDYA's Total Non-Current Liabilities are $81.8 million (Q3 2021), $88.1 million (Q2 2021), and $93.0 million (Q1 2021).